4.4 Article

An Individualized Exercise Intervention for People with Multiple Myeloma-Study Protocol of a Randomized Waitlist-Controlled Trial

Journal

CURRENT ONCOLOGY
Volume 29, Issue 2, Pages 901-923

Publisher

MDPI
DOI: 10.3390/curroncol29020077

Keywords

& nbsp;exercise ; physical activity; multiple myeloma; hematology; adherence; bone lesions; randomized controlled trial; quality of life; cost-effectiveness

Categories

Funding

  1. Australian Governments Medical Research Futures Fund (MRFF) Rapid Applied Research Translation Grant
  2. Health Translation Queensland
  3. Brisbane Diamantina Health Partners Cancer Theme Grant
  4. HABS-Medicine Research Collaboration Seeding Grant, The University of Queensland

Ask authors/readers for more resources

This study aims to evaluate the effectiveness of exercise intervention on health-related quality of life in multiple myeloma patients. Through a randomized controlled trial, patients will be divided into exercise group and control group to observe and record changes in multiple indicators, including bone health and pain, fatigue, cardiorespiratory fitness, muscle strength, body composition, disease response, and blood biomarkers. The findings will provide evidence for determining whether exercise should be included as part of standard myeloma care.
People with multiple myeloma (MM) are second only to people with lung cancer for the poorest reported health-related quality of life (HRQoL) of all cancer types. Whether exercise can improve HRQoL in MM, where bone pain and lesions are common, requires investigation. This trial aims to evaluate the efficacy of an exercise intervention compared with control on HRQoL in people with MM. Following baseline testing, people with MM (n = 60) will be randomized to an exercise (EX) or waitlist control (WT) group. EX will complete 12-weeks of supervised (24 sessions) and unsupervised (12 sessions) individualized, modular multimodal exercise training. From weeks 12-52, EX continue unsupervised training thrice weekly, with one optional supervised group-based session weekly from weeks 12-24. The WT will be asked to maintain their current activity levels for the first 12-weeks, before completing the same protocol as EX for the following 52 weeks. Primary (patient-reported HRQoL) and secondary (bone health and pain, fatigue, cardiorespiratory fitness, muscle strength, body composition, disease response, and blood biomarkers) outcomes will be assessed at baseline, 12-, 24- and 52-weeks. Adverse events, attendance, and adherence will be recorded and cost-effectiveness analysis performed. The findings will inform whether exercise should be included as part of standard myeloma care to improve the health of this unique population.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available